These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

914 related articles for article (PubMed ID: 24661807)

  • 1. Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS.
    Fitian AI; Nelson DR; Liu C; Xu Y; Ararat M; Cabrera R
    Liver Int; 2014 Oct; 34(9):1428-44. PubMed ID: 24661807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted metabolic profiling of hepatocellular carcinoma and hepatitis C using LC-MS/MS.
    Baniasadi H; Gowda GA; Gu H; Zeng A; Zhuang S; Skill N; Maluccio M; Raftery D
    Electrophoresis; 2013 Oct; 34(19):2910-7. PubMed ID: 23856972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling.
    Patterson AD; Maurhofer O; Beyoglu D; Lanz C; Krausz KW; Pabst T; Gonzalez FJ; Dufour JF; Idle JR
    Cancer Res; 2011 Nov; 71(21):6590-600. PubMed ID: 21900402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma.
    Chen T; Xie G; Wang X; Fan J; Qiu Y; Zheng X; Qi X; Cao Y; Su M; Wang X; Xu LX; Yen Y; Liu P; Jia W
    Mol Cell Proteomics; 2011 Jul; 10(7):M110.004945. PubMed ID: 21518826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [High-performance liquid chromatography-mass spectrometry-based serum metabolic profiling in patients with HBV-related hepatocellular carcinoma].
    Zhang L; Fan Z; Kang H; Wang Y; Liu S; Shan Z
    Nan Fang Yi Ke Da Xue Xue Bao; 2019 Jan; 39(1):49-56. PubMed ID: 30692066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis.
    Ressom HW; Xiao JF; Tuli L; Varghese RS; Zhou B; Tsai TH; Ranjbar MR; Zhao Y; Wang J; Di Poto C; Cheema AK; Tadesse MG; Goldman R; Shetty K
    Anal Chim Acta; 2012 Sep; 743():90-100. PubMed ID: 22882828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry.
    Wang B; Chen D; Chen Y; Hu Z; Cao M; Xie Q; Chen Y; Xu J; Zheng S; Li L
    J Proteome Res; 2012 Feb; 11(2):1217-27. PubMed ID: 22200553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis.
    Liu Y; Hong Z; Tan G; Dong X; Yang G; Zhao L; Chen X; Zhu Z; Lou Z; Qian B; Zhang G; Chai Y
    Int J Cancer; 2014 Aug; 135(3):658-68. PubMed ID: 24382646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of hepatocellular carcinoma in hepatitis C patients: biomarker discovery by LC-MS.
    Bowers J; Hughes E; Skill N; Maluccio M; Raftery D
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Sep; 966():154-62. PubMed ID: 24666728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of 1-Methylnicotinamide as a specific biomarker for the progression of cirrhosis to hepatocellular carcinoma.
    Zhang S; Tuo P; Ji Y; Huang Z; Xiong Z; Li H; Ruan C
    J Cancer Res Clin Oncol; 2024 Jun; 150(6):310. PubMed ID: 38890166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolomic Characterization of Hepatocellular Carcinoma in Patients with Liver Cirrhosis for Biomarker Discovery.
    Di Poto C; Ferrarini A; Zhao Y; Varghese RS; Tu C; Zuo Y; Wang M; Nezami Ranjbar MR; Luo Y; Zhang C; Desai CS; Shetty K; Tadesse MG; Ressom HW
    Cancer Epidemiol Biomarkers Prev; 2017 May; 26(5):675-683. PubMed ID: 27913395
    [No Abstract]   [Full Text] [Related]  

  • 12. Serum Metabolomics to Identify the Liver Disease-Specific Biomarkers for the Progression of Hepatitis to Hepatocellular Carcinoma.
    Gao R; Cheng J; Fan C; Shi X; Cao Y; Sun B; Ding H; Hu C; Dong F; Yan X
    Sci Rep; 2015 Dec; 5():18175. PubMed ID: 26658617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fecal metabolome profiling of liver cirrhosis and hepatocellular carcinoma patients by ultra performance liquid chromatography-mass spectrometry.
    Cao H; Huang H; Xu W; Chen D; Yu J; Li J; Li L
    Anal Chim Acta; 2011 Apr; 691(1-2):68-75. PubMed ID: 21458633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort.
    Xiao JF; Varghese RS; Zhou B; Nezami Ranjbar MR; Zhao Y; Tsai TH; Di Poto C; Wang J; Goerlitz D; Luo Y; Cheema AK; Sarhan N; Soliman H; Tadesse MG; Ziada DH; Ressom HW
    J Proteome Res; 2012 Dec; 11(12):5914-23. PubMed ID: 23078175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum amino acid metabolic profiles of ankylosing spondylitis by targeted metabolomics analysis.
    Zhou Y; Zhang X; Chen R; Han S; Liu Y; Liu X; Gao M; Yang C; Lu D; Sun B; Chen H
    Clin Rheumatol; 2020 Aug; 39(8):2325-2336. PubMed ID: 32130577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediagnostic concentrations of circulating bile acids and hepatocellular carcinoma risk: REVEAL-HBV and HCV studies.
    Petrick JL; Florio AA; Koshiol J; Pfeiffer RM; Yang B; Yu K; Chen CJ; Yang HI; Lee MH; McGlynn KA
    Int J Cancer; 2020 Nov; 147(10):2743-2753. PubMed ID: 32406072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omega-6-derived oxylipin changes in serum of patients with hepatitis B virus-related liver diseases.
    Lu Y; Fang J; Zou L; Cui L; Liang X; Lim SG; Dan YY; Ong CN
    Metabolomics; 2018 Jan; 14(3):26. PubMed ID: 30830341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pseudotargeted metabolomics method and its application in serum biomarker discovery for hepatocellular carcinoma based on ultra high-performance liquid chromatography/triple quadrupole mass spectrometry.
    Chen S; Kong H; Lu X; Li Y; Yin P; Zeng Z; Xu G
    Anal Chem; 2013 Sep; 85(17):8326-33. PubMed ID: 23889541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma metabolomic profiles in liver cancer patients following stereotactic body radiotherapy.
    Ng SSW; Jang GH; Kurland IJ; Qiu Y; Guha C; Dawson LA
    EBioMedicine; 2020 Sep; 59():102973. PubMed ID: 32891936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolomic Analysis of Liver Tissues for Characterization of Hepatocellular Carcinoma.
    Ferrarini A; Di Poto C; He S; Tu C; Varghese RS; Kara Balla A; Jayatilake M; Li Z; Ghaffari K; Fan Z; Sherif ZA; Kumar D; Kroemer A; Tadesse MG; Ressom HW
    J Proteome Res; 2019 Aug; 18(8):3067-3076. PubMed ID: 31188000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.